Protheragen
Obesity



Brivanib (BMS-540215)

Cat. No.:	OB0225WX-2390
Appearance:	Solid
Purity:	≥99%
Identity:	Confirmed by NMR, and HPLC.
Size:	5 mg; 10 mg; 50 mg; 200 mg

This product is for research use only and is not intended for diagnostic use.

Product Overview

Description	Brivanib (BMS-540215) is an ATP-competitive small molecule that selectively inhi bits VEGFR2 (IC50: 25 nM) while exhibiting moderate potency toward VEGFR-1 and F GFR-1.
Synonym	649735-46-6; Brivanib; Brivanib (BMS-540215); BMS-540215; BMS 540215; BMS540215; (2*R*)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol; 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-2-propanol; (2*R*)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]o xypropan-2-ol; (*R*)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrr olo(2,1-f)(1,2,4)triazin-6-yloxy)propan-2-ol; (*R*)-1-(4-(4-fluoro-2-methyl -1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol; 2-P ropanol, 1-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo(2,1-f)(1,2 ,4)triazin-6-yl)oxy)-, (2*R*)-; (*R*)-1-(4-(4-fluoro-2-methyl-1H-indol -5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazin-6-yloxy)propan-2-ol
CAS No.	649735-46-6
Compound CID	11234052
Formula	$C_{19}H_{19}FN_4O_3$
Formula Weight	370.38

Specification

Address: 101-4 Colin Dr, Holbrook, NY 11741, USA
Phone: 1-631-506-1393
info@obesityscientific.com

Protheragen Obesity



IUPAC Name	(2*R*)-1-[4-[(4-Fluoro-2-methyl-1*H*-indol-5-yl)oxy]-5-methylpyrrolo[2 ,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol
InChI	InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1
InChI Key	WCWUXEGQKLTGDX-LLVKDONJSA-N
SMILES string	CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)O)C
Stability	3 years in powder form.
Storage	Storage at -20°C.
Applications	Brivanib (BMS-540215) is applied in hepatology and oncology research as a dual V EGFR and FGFR inhibitor to examine the prevention of fibrotic progression and th e inhibition of hepatocellular carcinoma growth.

Library Information

Target	FGFR; VEGFR
Receptor	FGFR; VEGFR
Pathways	Protein tyrosine kinase
Plate Number	L6700-01
Empty Location	a1-h1; a12-h12
Container	96-well plate
Formulation	10mM DMSO
DMSO Max Solubility	74 mg/mL; 199.79 mM
ALogP	3.481
HBA_Count	4
HBD_Count	2
Rotatable Bond	5

Address: 101-4 Colin Dr, Holbrook, NY 11741, USA
Phone: 1-631-506-1393
info@obesityscientific.com